Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arecor and GlaxoSmithKline (GSK) have signed a licensing pact for the development of enhanced formulation of vaccines by combining GSK's proprietary vaccines with Arecor's formulation technologies.
Subscribe to our email newsletter
The companies will work together for the development of new approaches to improve administration of several vaccines in development.
As per the terms of the agreement, Arecor licenses its technology to GSK and will be eligible to get milestone payments and royalties on sales from GSK.
Arecor CEO Tom Saylor said the relationship with GSK offers the company the potential to apply its expertise in biomolecule stabilization to specific projects with GSK.